Neuropathic Pain – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：416頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Neuropathic Pain – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, H2 2012', provides an overview of the Neuropathic Pain therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. 'Neuropathic Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Neuropathic Pain.
- A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Neuropathic Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, H2 2012', provides an overview of the Neuropathic Pain therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. 'Neuropathic Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Neuropathic Pain.
- A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Neuropathic Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Neuropathic Pain Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Neuropathic Pain 15
Neuropathic Pain Therapeutics under Development by Companies 17
Neuropathic Pain Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Neuropathic Pain Therapeutics – Products under Development by Companies 32
Neuropathic Pain Therapeutics – Products under Investigation by Universities/Institutes 41
Companies Involved in Neuropathic Pain Therapeutics Development 43
Bristol-Myers Squibb Company 43
Genzyme Corporation 44
DURECT Corporation 45
Kyowa Hakko Kirin Co., Ltd. 46
Abbott Laboratories 47
Biogen Idec Inc. 48
Allergan, Inc. 49
Shionogi & Co., Ltd. 50
NsGene A/S 51
Valeant Pharmaceuticals International 52
Amgen Inc. 53
Sanofi-Aventis 54
AstraZeneca PLC 55
BioDelivery Sciences International, Inc. 56
Nektar Therapeutics 57
Quark Pharmaceuticals, Inc. 58
Daiichi Sankyo Company, Ltd 59
Sangamo BioSciences, Inc. 60
BioLineRx, Ltd. 61
Astellas Pharma Inc. 62
Daewoong Pharmaceutical Co., Ltd. 63
Glenmark Pharmaceuticals Ltd. 64
Pfizer Inc. 65
Purdue Pharma L.P. 66
EpiCept Corporation 67
Evotec Aktiengesellschaft 68
GW Pharmaceuticals plc 69
Anavex Life Sciences Corp. 70
AVANIR Pharmaceuticals 71
Lpath, Inc. 72
Medivir AB 73
Benitec Ltd. 74
NeurogesX, Inc. 75
NPS Pharmaceuticals, Inc. 76
Nuvo Research Inc. 77
Pharmos Corporation 78
CombinatoRx, Incorporated 79
Torrent Pharmaceuticals Limited 80
Diamyd Medical AB 81
Neurim Pharmaceuticals (1991) Ltd. 82
Pluristem Therapeutics Inc. 83
DARA BioSciences, Inc. 84
Proximagen Neuroscience plc. 85
Newron Pharmaceuticals S.p.A. 86
Angelini Group 87
Debiopharm Group 88
D-Pharm Ltd. 89
Auspex Pharmaceuticals 90
VistaGen Therapeutics , Inc. 91
Palau Pharma S.A 92
Snowdon Inc. 93
Neurotune AG 94
Xenon Pharmaceuticals Inc. 95
CREABILIS Therapeutics S.r.l. 96
Amura Holdings Ltd. 97
Affectis Pharmaceuticals AG 98
AngioChem Inc. 99
Chlorion Pharma, Inc. 100
PharmEste 101
Arcion Therapeutics, Inc. 102
WEX Pharmaceuticals Inc. 103
Hydra Biosciences, Inc. 104
Yaupon Therapeutics, Inc. 105
NeurAxon, Inc. 106
Virobay Inc. 107
Concert Pharmaceuticals, Inc. 108
QRxPharma Limited 109
Cara Therapeutics, Inc. 110
KYORIN Pharmaceutical Co., Ltd. 111
Lectus Therapeutics Limited 112
Lipopharma 113
Winston Pharmaceuticals, Inc. 114
Medisyn Technologies, Inc. 115
Maruho Co.,Ltd. 116
SantoSolve AS 117
Bial - Portela & Ca, S.A. 118
Spinifex Pharmaceuticals Pty Limited 119
TheraQuest Biosciences, LLC 120
Celtic Pharmaceutical Holdings L.P. 121
RaQualia Pharma Inc. 122
Mt Cook Pharma. Inc. 123
Naurex, Inc. 124
Cytogel Pharma, LLC 125
Neuropathic Pain – Therapeutics Assessment 126
Assessment by Monotherapy Products 126
Assessment by Combination Products 127
Assessment by Route of Administration 128
Assessment by Molecule Type 131
Drug Profiles 134
Neublastin - Drug Profile 134
Lyrica - Drug Profile 136
SEP-228432 - Drug Profile 138
AZD2423 - Drug Profile 139
AVP-923 - Drug Profile 140
AVP-923 - Drug Profile 142
P2X3 and P2X2/3 Antagonist - Drug Profile 144
B1 Antagonists - Drug Profile 145
Lpathomab - Drug Profile 146
Sativex - Drug Profile 147
NKTR-171 - Drug Profile 149
SD-254 - Drug Profile 150
NPSP-156 - Drug Profile 151
CSC 700 Series - Drug Profile 152
SND-121 - Drug Profile 153
NT-11624 - Drug Profile 154
Debio 0827 - Drug Profile 156
Cathepsin S Inhibitors - Drug Profile 157
NG2 GAD - Drug Profile 159
BL-1021 - Drug Profile 160
CR 4056 - Drug Profile 161
CR 3719 Series - Drug Profile 162
Stedesa - Drug Profile 163
UR-13870 - Drug Profile 165
CT327 - Drug Profile 166
Eladur - Drug Profile 168
KRN5500 - Drug Profile 170
Ketas - Drug Profile 172
NGX-1998 - Drug Profile 174
AmiKet - Drug Profile 176
BEMA Buprenorphine - Drug Profile 177
Civanex Nasal Solution - Drug Profile 179
PRS-639, 058 - Drug Profile 180
NXN-462 - Drug Profile 181
Tectin - Drug Profile 182
IPI-940 - Drug Profile 184
ZFP TFs For Neuropathic Pain - Drug Profile 185
VBY-036 - Drug Profile 186
ANAVEX-1007 - Drug Profile 187
MoxDuo CR - Drug Profile 188
Topical XEN-402 - Drug Profile 190
HC-030031 - Drug Profile 191
YT-1006 - Drug Profile 193
PHE377 - Drug Profile 194
Neuroprotection And Neural Regeneration Program - Drug Profile 195
HF-0299 - Drug Profile 196
SKL NP - Drug Profile 197
ralfinamide - Drug Profile 198
Oxycodone + Pregabalin - Drug Profile 199
AV-101 - Drug Profile 200
Neuroderm Patch - Drug Profile 201
BVT.115959 - Drug Profile 203
Gamma Protein kinase C Inhibitor Program - Drug Profile 204
Cav2.2 - Drug Profile 205
KAI-1678 - Drug Profile 206
GRT6005 - Drug Profile 208
IMX-150 - Drug Profile 209
CLP-290 - Drug Profile 210
EHT/AGN 0001 - Drug Profile 211
Ketamine - Drug Profile 212
Z160 - Drug Profile 213
Cathepsin S Program - Drug Profile 214
RQ-00203066 - Drug Profile 215
Drug For Neuropathic Pain - Drug Profile 216
YKP3089 - Drug Profile 217
Oral Civamide - Drug Profile 219
NsG34 - Drug Profile 220
NsG33 - Drug Profile 221
NsG-33 - Drug Profile 223
Marijuana - Drug Profile 224
Tramadol - Drug Profile 225
Marijuana - Drug Profile 226
Amitriptyline - Drug Profile 227
Pregabalin - Drug Profile 228
Lidocaine - Drug Profile 229
Capsaicin - Drug Profile 230
Lidocaine Patch - Drug Profile 231
Pregabalin - Drug Profile 233
Amitriptyline + Ketamine + Lidocaine - Drug Profile 234
SAR-292833 - Drug Profile 235
Sativex - Drug Profile 237
Etoricoxib - Drug Profile 239
AGN-214868 - Drug Profile 240
Gabapentin + Donepezil - Drug Profile 241
Gabapentin + Venlafaxine - Drug Profile 242
Paxil - Drug Profile 243
Plasmid VEGF Gene Transfer - Drug Profile 244
GLYX-13 - Drug Profile 245
ANAVEX-1519 - Drug Profile 247
ANAVEX-1079 - Drug Profile 248
Ketamine - Drug Profile 249
ATx09-002 - Drug Profile 250
Gabapentin - Drug Profile 252
ANG2002 - Drug Profile 254
ABT-652 - Drug Profile 255
AM-3840 - Drug Profile 256
DWP05195 - Drug Profile 257
Trobalt - Drug Profile 259
2PX - Drug Profile 261
MCP-1/CCL2 + Selected CytoKines Productions Inhibitors - Drug Profile 263
XPF-002 - Drug Profile 264
AFC-5128 - Drug Profile 265
Intravenous immunoglobulin + Normal Saline - Drug Profile 266
Intravenous immunoglobulin + Normal Saline - Drug Profile 267
Varicella-Zoster Vaccine - Drug Profile 268
Ketamine - Drug Profile 269
Amitriptyline - Drug Profile 270
Nabilone - Drug Profile 271
RQ-00203078 - Drug Profile 272
Nav 1.7 Blocker Program - Drug Profile 273
T-Ca (Cav3.2) Blocker Program - Drug Profile 274
GRC 17536 - Drug Profile 275
CR701 - Drug Profile 276
EMA401 - Drug Profile 277
Botox - Drug Profile 279
Neu-P12 - Drug Profile 280
PHE575 - Drug Profile 281
NCE 3 - Drug Profile 282
DS-5565 - Drug Profile 283
AF3473 - Drug Profile 284
LPA181 - Drug Profile 285
KHK6188 - Drug Profile 286
CNSB015 - Drug Profile 287
CNSB007 - Drug Profile 288
CNSB002 - Drug Profile 289
TQ-1020 - Drug Profile 290
TQ-1021 - Drug Profile 291
Z-212 - Drug Profile 293
BMS-954561 - Drug Profile 294
Versatis - Drug Profile 295
ATx08-001 - Drug Profile 296
Oral XEN-402 - Drug Profile 298
Milnacipran - Drug Profile 299
T270 - Drug Profile 300
ABT-639 - Drug Profile 301
C-10068 - Drug Profile 302
PLX For Neuropathic and Inflammatory Pain - Drug Profile 304
DP-236 - Drug Profile 305
ARC 2022 - Drug Profile 306
MCP-204 - Drug Profile 307
Hypericin - Drug Profile 308
MDA19 - Drug Profile 309
ANAVEX-1066 - Drug Profile 310
LASSBio-873 - Drug Profile 311
WIN 55,212-2 - Drug Profile 313
NRX-1050 Series - Drug Profile 314
CTP-354 - Drug Profile 315
NRI-ANA - Drug Profile 316
CNV1014802 - Drug Profile 317
THA901 - Drug Profile 319
THA904 - Drug Profile 320
Methadone Hydrochloride - Drug Profile 321
BL-7050 - Drug Profile 323
Cannabidiol - Drug Profile 324
Cyt-1010 - Drug Profile 325
ddRNAi Program For Cancer-Associated Pain - Drug Profile 327
ASP9226 - Drug Profile 329
ASP8477 - Drug Profile 330
ABT-594 - Drug Profile 331
CNSB001 - Drug Profile 333
HZ 166 - Drug Profile 334
RAP103 - Drug Profile 336
AZ889 - Drug Profile 337
S-117957 - Drug Profile 338
Nav1.8 Sodium Channel Blocker - Drug Profile 339
NR2B Program For Neuropathic Pain - Drug Profile 340
Drug For Neuropathic Pain - Drug Profile 341
Neuropathic Pain Program - Drug Profile 342
NQ1065 - Drug Profile 343
AP-325 - Drug Profile 344
AYX-3 - Drug Profile 345
Genetically Modified Adult Stem Cells - Drug Profile 346
Neuropathic Pain Therapeutics – Drug Profile Updates 347
Neuropathic Pain Therapeutics – Discontinued Products 385
Neuropathic Pain Therapeutics - Dormant Products 390
Neuropathic Pain – Product Development Milestones 397
Featured News & Press Releases 397
Appendix 403
Methodology 403
Coverage 403
Secondary Research 403
Primary Research 403
Expert Panel Validation 403
Contact Us 404
Disclaimer 404
List of Tables
Number of Products Under Development for Neuropathic Pain, H2 2012 27
Products under Development for Neuropathic Pain – Comparative Analysis, H2 2012 28
Number of Products under Development by Companies, H2 2012 30
Number of Products under Development by Companies, H2 2012 (Contd..1) 31
Number of Products under Development by Companies, H2 2012 (Contd..2) 32
Number of Products under Development by Companies, H2 2012 (Contd..3) 33
Number of Products under Development by Companies, H2 2012 (Contd..4) 34
Number of Products under Development by Companies, H2 2012 (Contd..5) 35
Number of Products under Development by Companies, H2 2012 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Comparative Analysis by Late Stage Development, H2 2012 40
Comparative Analysis by Mid Clinical Stage Development, H2 2012 41
Comparative Analysis by Early Clinical Stage Development, H2 2012 42
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 43
Products under Development by Companies, H2 2012 44
Products under Development by Companies, H2 2012 (Contd..1) 45
Products under Development by Companies, H2 2012 (Contd..2) 46
Products under Development by Companies, H2 2012 (Contd..3) 47
Products under Development by Companies, H2 2012 (Contd..4) 48
Products under Development by Companies, H2 2012 (Contd..5) 49
Products under Development by Companies, H2 2012 (Contd..6) 50
Products under Development by Companies, H2 2012 (Contd..7) 51
Products under Development by Companies, H2 2012 (Contd..8) 52
Products under Investigation by Universities/Institutes, H2 2012 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 54
Bristol-Myers Squibb Company, H2 2012 55
Genzyme Corporation, H2 2012 56
DURECT Corporation, H2 2012 57
Kyowa Hakko Kirin Co., Ltd., H2 2012 58
Abbott Laboratories, H2 2012 59
Biogen Idec Inc., H2 2012 60
Allergan, Inc., H2 2012 61
Shionogi & Co., Ltd., H2 2012 62
NsGene A/S, H2 2012 63
Valeant Pharmaceuticals International, H2 2012 64
Amgen Inc., H2 2012 65
Sanofi-Aventis, H2 2012 66
AstraZeneca PLC, H2 2012 67
BioDelivery Sciences International, Inc., H2 2012 68
Nektar Therapeutics, H2 2012 69
Quark Pharmaceuticals, Inc., H2 2012 70
Daiichi Sankyo Company, Ltd, H2 2012 71
Sangamo BioSciences, Inc., H2 2012 72
BioLineRx, Ltd., H2 2012 73
Astellas Pharma Inc., H2 2012 74
Daewoong Pharmaceutical Co., Ltd., H2 2012 75
Glenmark Pharmaceuticals Ltd., H2 2012 76
Pfizer Inc., H2 2012 77
Purdue Pharma L.P., H2 2012 78
EpiCept Corporation, H2 2012 79
Evotec Aktiengesellschaft, H2 2012 80
GW Pharmaceuticals plc, H2 2012 81
Anavex Life Sciences Corp., H2 2012 82
AVANIR Pharmaceuticals, H2 2012 83
Lpath, Inc., H2 2012 84
Medivir AB, H2 2012 85
Benitec Ltd., H2 2012 86
NeurogesX, Inc., H2 2012 87
NPS Pharmaceuticals, Inc., H2 2012 88
Nuvo Research Inc., H2 2012 89
Pharmos Corporation, H2 2012 90
CombinatoRx, Incorporated, H2 2012 91
Torrent Pharmaceuticals Limited, H2 2012 92
Diamyd Medical AB, H2 2012 93
Neurim Pharmaceuticals (1991) Ltd., H2 2012 94
Pluristem Therapeutics Inc., H2 2012 95
DARA BioSciences, Inc., H2 2012 96
Proximagen Neuroscience plc., H2 2012 97
Newron Pharmaceuticals S.p.A., H2 2012 98
Angelini Group, H2 2012 99
Debiopharm Group, H2 2012 100
D-Pharm Ltd., H2 2012 101
Auspex Pharmaceuticals, H2 2012 102
VistaGen Therapeutics , Inc., H2 2012 103
Palau Pharma S.A, H2 2012 104
Snowdon Inc., H2 2012 105
Neurotune AG, H2 2012 106
Xenon Pharmaceuticals Inc., H2 2012 107
CREABILIS Therapeutics S.r.l., H2 2012 108
Amura Holdings Ltd., H2 2012 109
Affectis Pharmaceuticals AG, H2 2012 110
AngioChem Inc., H2 2012 111
Chlorion Pharma, Inc., H2 2012 112
PharmEste, H2 2012 113
Arcion Therapeutics, Inc., H2 2012 114
WEX Pharmaceuticals Inc., H2 2012 115
Hydra Biosciences, Inc., H2 2012 116
Yaupon Therapeutics, Inc., H2 2012 117
NeurAxon, Inc., H2 2012 118
Virobay Inc., H2 2012 119
Concert Pharmaceuticals, Inc., H2 2012 120
QRxPharma Limited, H2 2012 121
Cara Therapeutics, Inc., H2 2012 122
KYORIN Pharmaceutical Co., Ltd., H2 2012 123
Lectus Therapeutics Limited, H2 2012 124
Lipopharma, H2 2012 125
Winston Pharmaceuticals, Inc., H2 2012 126
Medisyn Technologies, Inc., H2 2012 127
Maruho Co.,Ltd., H2 2012 128
SantoSolve AS, H2 2012 129
Bial - Portela & Ca, S.A., H2 2012 130
Spinifex Pharmaceuticals Pty Limited, H2 2012 131
TheraQuest Biosciences, LLC, H2 2012 132
Celtic Pharmaceutical Holdings L.P., H2 2012 133
RaQualia Pharma Inc., H2 2012 134
Mt Cook Pharma. Inc., H2 2012 135
Naurex, Inc., H2 2012 136
Cytogel Pharma, LLC, H2 2012 137
Assessment by Monotherapy Products, H2 2012 138
Assessment by Combination Products, H2 2012 139
Assessment by Stage and Route of Administration, H2 2012 142
Assessment by Stage and Molecule Type, H2 2012 145
Neuropathic Pain Therapeutics – Drug Profile Updates 359
Neuropathic Pain Therapeutics – Discontinued Products 397
Neuropathic Pain Therapeutics – Discontinued Products (Contd..1) 398
Neuropathic Pain Therapeutics – Discontinued Products (Contd..2) 399
Neuropathic Pain Therapeutics – Discontinued Products (Contd..3) 400
Neuropathic Pain Therapeutics – Discontinued Products (Contd..4) 401
Neuropathic Pain Therapeutics – Dormant Products 402
Neuropathic Pain Therapeutics – Dormant Products (Contd..1) 403
Neuropathic Pain Therapeutics – Dormant Products (Contd..2) 404
Neuropathic Pain Therapeutics – Dormant Products (Contd..3) 405
Neuropathic Pain Therapeutics – Dormant Products (Contd..4) 406
Neuropathic Pain Therapeutics – Dormant Products (Contd..5) 407
Neuropathic Pain Therapeutics – Dormant Products (Contd..6) 408
List of Figures
Number of Products under Development for Neuropathic Pain, H2 2012 27
Products under Development for Neuropathic Pain – Comparative Analysis, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 37
Late Stage Products, H2 2012 40
Mid Clinical Stage Products, H2 2012 41
Early Clinical Stage Products, H2 2012 42
Discovery and Pre-Clinical Stage Products, H2 2012 43
Assessment by Monotherapy Products, H2 2012 138
Assessment by Combination Products, H2 2012 139
Assessment by Route of Administration, H2 2012 140
Assessment by Stage and Route of Administration, H2 2012 141
Assessment by Molecule Type, H2 2012 143
Assessment by Stage and Molecule Type, H2 2012 144
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Neuropathic Pain Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Neuropathic Pain 15
Neuropathic Pain Therapeutics under Development by Companies 17
Neuropathic Pain Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Neuropathic Pain Therapeutics – Products under Development by Companies 32
Neuropathic Pain Therapeutics – Products under Investigation by Universities/Institutes 41
Companies Involved in Neuropathic Pain Therapeutics Development 43
Bristol-Myers Squibb Company 43
Genzyme Corporation 44
DURECT Corporation 45
Kyowa Hakko Kirin Co., Ltd. 46
Abbott Laboratories 47
Biogen Idec Inc. 48
Allergan, Inc. 49
Shionogi & Co., Ltd. 50
NsGene A/S 51
Valeant Pharmaceuticals International 52
Amgen Inc. 53
Sanofi-Aventis 54
AstraZeneca PLC 55
BioDelivery Sciences International, Inc. 56
Nektar Therapeutics 57
Quark Pharmaceuticals, Inc. 58
Daiichi Sankyo Company, Ltd 59
Sangamo BioSciences, Inc. 60
BioLineRx, Ltd. 61
Astellas Pharma Inc. 62
Daewoong Pharmaceutical Co., Ltd. 63
Glenmark Pharmaceuticals Ltd. 64
Pfizer Inc. 65
Purdue Pharma L.P. 66
EpiCept Corporation 67
Evotec Aktiengesellschaft 68
GW Pharmaceuticals plc 69
Anavex Life Sciences Corp. 70
AVANIR Pharmaceuticals 71
Lpath, Inc. 72
Medivir AB 73
Benitec Ltd. 74
NeurogesX, Inc. 75
NPS Pharmaceuticals, Inc. 76
Nuvo Research Inc. 77
Pharmos Corporation 78
CombinatoRx, Incorporated 79
Torrent Pharmaceuticals Limited 80
Diamyd Medical AB 81
Neurim Pharmaceuticals (1991) Ltd. 82
Pluristem Therapeutics Inc. 83
DARA BioSciences, Inc. 84
Proximagen Neuroscience plc. 85
Newron Pharmaceuticals S.p.A. 86
Angelini Group 87
Debiopharm Group 88
D-Pharm Ltd. 89
Auspex Pharmaceuticals 90
VistaGen Therapeutics , Inc. 91
Palau Pharma S.A 92
Snowdon Inc. 93
Neurotune AG 94
Xenon Pharmaceuticals Inc. 95
CREABILIS Therapeutics S.r.l. 96
Amura Holdings Ltd. 97
Affectis Pharmaceuticals AG 98
AngioChem Inc. 99
Chlorion Pharma, Inc. 100
PharmEste 101
Arcion Therapeutics, Inc. 102
WEX Pharmaceuticals Inc. 103
Hydra Biosciences, Inc. 104
Yaupon Therapeutics, Inc. 105
NeurAxon, Inc. 106
Virobay Inc. 107
Concert Pharmaceuticals, Inc. 108
QRxPharma Limited 109
Cara Therapeutics, Inc. 110
KYORIN Pharmaceutical Co., Ltd. 111
Lectus Therapeutics Limited 112
Lipopharma 113
Winston Pharmaceuticals, Inc. 114
Medisyn Technologies, Inc. 115
Maruho Co.,Ltd. 116
SantoSolve AS 117
Bial - Portela & Ca, S.A. 118
Spinifex Pharmaceuticals Pty Limited 119
TheraQuest Biosciences, LLC 120
Celtic Pharmaceutical Holdings L.P. 121
RaQualia Pharma Inc. 122
Mt Cook Pharma. Inc. 123
Naurex, Inc. 124
Cytogel Pharma, LLC 125
Neuropathic Pain – Therapeutics Assessment 126
Assessment by Monotherapy Products 126
Assessment by Combination Products 127
Assessment by Route of Administration 128
Assessment by Molecule Type 131
Drug Profiles 134
Neublastin - Drug Profile 134
Lyrica - Drug Profile 136
SEP-228432 - Drug Profile 138
AZD2423 - Drug Profile 139
AVP-923 - Drug Profile 140
AVP-923 - Drug Profile 142
P2X3 and P2X2/3 Antagonist - Drug Profile 144
B1 Antagonists - Drug Profile 145
Lpathomab - Drug Profile 146
Sativex - Drug Profile 147
NKTR-171 - Drug Profile 149
SD-254 - Drug Profile 150
NPSP-156 - Drug Profile 151
CSC 700 Series - Drug Profile 152
SND-121 - Drug Profile 153
NT-11624 - Drug Profile 154
Debio 0827 - Drug Profile 156
Cathepsin S Inhibitors - Drug Profile 157
NG2 GAD - Drug Profile 159
BL-1021 - Drug Profile 160
CR 4056 - Drug Profile 161
CR 3719 Series - Drug Profile 162
Stedesa - Drug Profile 163
UR-13870 - Drug Profile 165
CT327 - Drug Profile 166
Eladur - Drug Profile 168
KRN5500 - Drug Profile 170
Ketas - Drug Profile 172
NGX-1998 - Drug Profile 174
AmiKet - Drug Profile 176
BEMA Buprenorphine - Drug Profile 177
Civanex Nasal Solution - Drug Profile 179
PRS-639, 058 - Drug Profile 180
NXN-462 - Drug Profile 181
Tectin - Drug Profile 182
IPI-940 - Drug Profile 184
ZFP TFs For Neuropathic Pain - Drug Profile 185
VBY-036 - Drug Profile 186
ANAVEX-1007 - Drug Profile 187
MoxDuo CR - Drug Profile 188
Topical XEN-402 - Drug Profile 190
HC-030031 - Drug Profile 191
YT-1006 - Drug Profile 193
PHE377 - Drug Profile 194
Neuroprotection And Neural Regeneration Program - Drug Profile 195
HF-0299 - Drug Profile 196
SKL NP - Drug Profile 197
ralfinamide - Drug Profile 198
Oxycodone + Pregabalin - Drug Profile 199
AV-101 - Drug Profile 200
Neuroderm Patch - Drug Profile 201
BVT.115959 - Drug Profile 203
Gamma Protein kinase C Inhibitor Program - Drug Profile 204
Cav2.2 - Drug Profile 205
KAI-1678 - Drug Profile 206
GRT6005 - Drug Profile 208
IMX-150 - Drug Profile 209
CLP-290 - Drug Profile 210
EHT/AGN 0001 - Drug Profile 211
Ketamine - Drug Profile 212
Z160 - Drug Profile 213
Cathepsin S Program - Drug Profile 214
RQ-00203066 - Drug Profile 215
Drug For Neuropathic Pain - Drug Profile 216
YKP3089 - Drug Profile 217
Oral Civamide - Drug Profile 219
NsG34 - Drug Profile 220
NsG33 - Drug Profile 221
NsG-33 - Drug Profile 223
Marijuana - Drug Profile 224
Tramadol - Drug Profile 225
Marijuana - Drug Profile 226
Amitriptyline - Drug Profile 227
Pregabalin - Drug Profile 228
Lidocaine - Drug Profile 229
Capsaicin - Drug Profile 230
Lidocaine Patch - Drug Profile 231
Pregabalin - Drug Profile 233
Amitriptyline + Ketamine + Lidocaine - Drug Profile 234
SAR-292833 - Drug Profile 235
Sativex - Drug Profile 237
Etoricoxib - Drug Profile 239
AGN-214868 - Drug Profile 240
Gabapentin + Donepezil - Drug Profile 241
Gabapentin + Venlafaxine - Drug Profile 242
Paxil - Drug Profile 243
Plasmid VEGF Gene Transfer - Drug Profile 244
GLYX-13 - Drug Profile 245
ANAVEX-1519 - Drug Profile 247
ANAVEX-1079 - Drug Profile 248
Ketamine - Drug Profile 249
ATx09-002 - Drug Profile 250
Gabapentin - Drug Profile 252
ANG2002 - Drug Profile 254
ABT-652 - Drug Profile 255
AM-3840 - Drug Profile 256
DWP05195 - Drug Profile 257
Trobalt - Drug Profile 259
2PX - Drug Profile 261
MCP-1/CCL2 + Selected CytoKines Productions Inhibitors - Drug Profile 263
XPF-002 - Drug Profile 264
AFC-5128 - Drug Profile 265
Intravenous immunoglobulin + Normal Saline - Drug Profile 266
Intravenous immunoglobulin + Normal Saline - Drug Profile 267
Varicella-Zoster Vaccine - Drug Profile 268
Ketamine - Drug Profile 269
Amitriptyline - Drug Profile 270
Nabilone - Drug Profile 271
RQ-00203078 - Drug Profile 272
Nav 1.7 Blocker Program - Drug Profile 273
T-Ca (Cav3.2) Blocker Program - Drug Profile 274
GRC 17536 - Drug Profile 275
CR701 - Drug Profile 276
EMA401 - Drug Profile 277
Botox - Drug Profile 279
Neu-P12 - Drug Profile 280
PHE575 - Drug Profile 281
NCE 3 - Drug Profile 282
DS-5565 - Drug Profile 283
AF3473 - Drug Profile 284
LPA181 - Drug Profile 285
KHK6188 - Drug Profile 286
CNSB015 - Drug Profile 287
CNSB007 - Drug Profile 288
CNSB002 - Drug Profile 289
TQ-1020 - Drug Profile 290
TQ-1021 - Drug Profile 291
Z-212 - Drug Profile 293
BMS-954561 - Drug Profile 294
Versatis - Drug Profile 295
ATx08-001 - Drug Profile 296
Oral XEN-402 - Drug Profile 298
Milnacipran - Drug Profile 299
T270 - Drug Profile 300
ABT-639 - Drug Profile 301
C-10068 - Drug Profile 302
PLX For Neuropathic and Inflammatory Pain - Drug Profile 304
DP-236 - Drug Profile 305
ARC 2022 - Drug Profile 306
MCP-204 - Drug Profile 307
Hypericin - Drug Profile 308
MDA19 - Drug Profile 309
ANAVEX-1066 - Drug Profile 310
LASSBio-873 - Drug Profile 311
WIN 55,212-2 - Drug Profile 313
NRX-1050 Series - Drug Profile 314
CTP-354 - Drug Profile 315
NRI-ANA - Drug Profile 316
CNV1014802 - Drug Profile 317
THA901 - Drug Profile 319
THA904 - Drug Profile 320
Methadone Hydrochloride - Drug Profile 321
BL-7050 - Drug Profile 323
Cannabidiol - Drug Profile 324
Cyt-1010 - Drug Profile 325
ddRNAi Program For Cancer-Associated Pain - Drug Profile 327
ASP9226 - Drug Profile 329
ASP8477 - Drug Profile 330
ABT-594 - Drug Profile 331
CNSB001 - Drug Profile 333
HZ 166 - Drug Profile 334
RAP103 - Drug Profile 336
AZ889 - Drug Profile 337
S-117957 - Drug Profile 338
Nav1.8 Sodium Channel Blocker - Drug Profile 339
NR2B Program For Neuropathic Pain - Drug Profile 340
Drug For Neuropathic Pain - Drug Profile 341
Neuropathic Pain Program - Drug Profile 342
NQ1065 - Drug Profile 343
AP-325 - Drug Profile 344
AYX-3 - Drug Profile 345
Genetically Modified Adult Stem Cells - Drug Profile 346
Neuropathic Pain Therapeutics – Drug Profile Updates 347
Neuropathic Pain Therapeutics – Discontinued Products 385
Neuropathic Pain Therapeutics - Dormant Products 390
Neuropathic Pain – Product Development Milestones 397
Featured News & Press Releases 397
Appendix 403
Methodology 403
Coverage 403
Secondary Research 403
Primary Research 403
Expert Panel Validation 403
Contact Us 404
Disclaimer 404
List of Tables
Number of Products Under Development for Neuropathic Pain, H2 2012 27
Products under Development for Neuropathic Pain – Comparative Analysis, H2 2012 28
Number of Products under Development by Companies, H2 2012 30
Number of Products under Development by Companies, H2 2012 (Contd..1) 31
Number of Products under Development by Companies, H2 2012 (Contd..2) 32
Number of Products under Development by Companies, H2 2012 (Contd..3) 33
Number of Products under Development by Companies, H2 2012 (Contd..4) 34
Number of Products under Development by Companies, H2 2012 (Contd..5) 35
Number of Products under Development by Companies, H2 2012 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Comparative Analysis by Late Stage Development, H2 2012 40
Comparative Analysis by Mid Clinical Stage Development, H2 2012 41
Comparative Analysis by Early Clinical Stage Development, H2 2012 42
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 43
Products under Development by Companies, H2 2012 44
Products under Development by Companies, H2 2012 (Contd..1) 45
Products under Development by Companies, H2 2012 (Contd..2) 46
Products under Development by Companies, H2 2012 (Contd..3) 47
Products under Development by Companies, H2 2012 (Contd..4) 48
Products under Development by Companies, H2 2012 (Contd..5) 49
Products under Development by Companies, H2 2012 (Contd..6) 50
Products under Development by Companies, H2 2012 (Contd..7) 51
Products under Development by Companies, H2 2012 (Contd..8) 52
Products under Investigation by Universities/Institutes, H2 2012 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 54
Bristol-Myers Squibb Company, H2 2012 55
Genzyme Corporation, H2 2012 56
DURECT Corporation, H2 2012 57
Kyowa Hakko Kirin Co., Ltd., H2 2012 58
Abbott Laboratories, H2 2012 59
Biogen Idec Inc., H2 2012 60
Allergan, Inc., H2 2012 61
Shionogi & Co., Ltd., H2 2012 62
NsGene A/S, H2 2012 63
Valeant Pharmaceuticals International, H2 2012 64
Amgen Inc., H2 2012 65
Sanofi-Aventis, H2 2012 66
AstraZeneca PLC, H2 2012 67
BioDelivery Sciences International, Inc., H2 2012 68
Nektar Therapeutics, H2 2012 69
Quark Pharmaceuticals, Inc., H2 2012 70
Daiichi Sankyo Company, Ltd, H2 2012 71
Sangamo BioSciences, Inc., H2 2012 72
BioLineRx, Ltd., H2 2012 73
Astellas Pharma Inc., H2 2012 74
Daewoong Pharmaceutical Co., Ltd., H2 2012 75
Glenmark Pharmaceuticals Ltd., H2 2012 76
Pfizer Inc., H2 2012 77
Purdue Pharma L.P., H2 2012 78
EpiCept Corporation, H2 2012 79
Evotec Aktiengesellschaft, H2 2012 80
GW Pharmaceuticals plc, H2 2012 81
Anavex Life Sciences Corp., H2 2012 82
AVANIR Pharmaceuticals, H2 2012 83
Lpath, Inc., H2 2012 84
Medivir AB, H2 2012 85
Benitec Ltd., H2 2012 86
NeurogesX, Inc., H2 2012 87
NPS Pharmaceuticals, Inc., H2 2012 88
Nuvo Research Inc., H2 2012 89
Pharmos Corporation, H2 2012 90
CombinatoRx, Incorporated, H2 2012 91
Torrent Pharmaceuticals Limited, H2 2012 92
Diamyd Medical AB, H2 2012 93
Neurim Pharmaceuticals (1991) Ltd., H2 2012 94
Pluristem Therapeutics Inc., H2 2012 95
DARA BioSciences, Inc., H2 2012 96
Proximagen Neuroscience plc., H2 2012 97
Newron Pharmaceuticals S.p.A., H2 2012 98
Angelini Group, H2 2012 99
Debiopharm Group, H2 2012 100
D-Pharm Ltd., H2 2012 101
Auspex Pharmaceuticals, H2 2012 102
VistaGen Therapeutics , Inc., H2 2012 103
Palau Pharma S.A, H2 2012 104
Snowdon Inc., H2 2012 105
Neurotune AG, H2 2012 106
Xenon Pharmaceuticals Inc., H2 2012 107
CREABILIS Therapeutics S.r.l., H2 2012 108
Amura Holdings Ltd., H2 2012 109
Affectis Pharmaceuticals AG, H2 2012 110
AngioChem Inc., H2 2012 111
Chlorion Pharma, Inc., H2 2012 112
PharmEste, H2 2012 113
Arcion Therapeutics, Inc., H2 2012 114
WEX Pharmaceuticals Inc., H2 2012 115
Hydra Biosciences, Inc., H2 2012 116
Yaupon Therapeutics, Inc., H2 2012 117
NeurAxon, Inc., H2 2012 118
Virobay Inc., H2 2012 119
Concert Pharmaceuticals, Inc., H2 2012 120
QRxPharma Limited, H2 2012 121
Cara Therapeutics, Inc., H2 2012 122
KYORIN Pharmaceutical Co., Ltd., H2 2012 123
Lectus Therapeutics Limited, H2 2012 124
Lipopharma, H2 2012 125
Winston Pharmaceuticals, Inc., H2 2012 126
Medisyn Technologies, Inc., H2 2012 127
Maruho Co.,Ltd., H2 2012 128
SantoSolve AS, H2 2012 129
Bial - Portela & Ca, S.A., H2 2012 130
Spinifex Pharmaceuticals Pty Limited, H2 2012 131
TheraQuest Biosciences, LLC, H2 2012 132
Celtic Pharmaceutical Holdings L.P., H2 2012 133
RaQualia Pharma Inc., H2 2012 134
Mt Cook Pharma. Inc., H2 2012 135
Naurex, Inc., H2 2012 136
Cytogel Pharma, LLC, H2 2012 137
Assessment by Monotherapy Products, H2 2012 138
Assessment by Combination Products, H2 2012 139
Assessment by Stage and Route of Administration, H2 2012 142
Assessment by Stage and Molecule Type, H2 2012 145
Neuropathic Pain Therapeutics – Drug Profile Updates 359
Neuropathic Pain Therapeutics – Discontinued Products 397
Neuropathic Pain Therapeutics – Discontinued Products (Contd..1) 398
Neuropathic Pain Therapeutics – Discontinued Products (Contd..2) 399
Neuropathic Pain Therapeutics – Discontinued Products (Contd..3) 400
Neuropathic Pain Therapeutics – Discontinued Products (Contd..4) 401
Neuropathic Pain Therapeutics – Dormant Products 402
Neuropathic Pain Therapeutics – Dormant Products (Contd..1) 403
Neuropathic Pain Therapeutics – Dormant Products (Contd..2) 404
Neuropathic Pain Therapeutics – Dormant Products (Contd..3) 405
Neuropathic Pain Therapeutics – Dormant Products (Contd..4) 406
Neuropathic Pain Therapeutics – Dormant Products (Contd..5) 407
Neuropathic Pain Therapeutics – Dormant Products (Contd..6) 408
List of Figures
Number of Products under Development for Neuropathic Pain, H2 2012 27
Products under Development for Neuropathic Pain – Comparative Analysis, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 37
Late Stage Products, H2 2012 40
Mid Clinical Stage Products, H2 2012 41
Early Clinical Stage Products, H2 2012 42
Discovery and Pre-Clinical Stage Products, H2 2012 43
Assessment by Monotherapy Products, H2 2012 138
Assessment by Combination Products, H2 2012 139
Assessment by Route of Administration, H2 2012 140
Assessment by Stage and Route of Administration, H2 2012 141
Assessment by Molecule Type, H2 2012 143
Assessment by Stage and Molecule Type, H2 2012 144
